Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.93 USD
Change Today -0.06 / -0.75%
Volume 138.8K
As of 8:10 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

zosano pharma corp (ZSAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/15 - $12.40
52 Week Low
06/2/15 - $7.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZOSANO PHARMA CORP (ZSAN)

Related News

No related news articles were found.

zosano pharma corp (ZSAN) Related Businessweek News

No Related Businessweek News Found

zosano pharma corp (ZSAN) Details

Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The company’s lead product candidates include Daily ZP-PTH, a synthetic form of parathyroid hormone for treating severe osteoporosis, which has completed a Phase II trial; ZP-Glucagon, a hormone that raises blood glucose levels, intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia, which is in Phase II clinical trial; and ZP-Triptan, a class of serotonin receptor agonists known as triptans, used for the treatment of migraine, which is in Phase I and II clinical trials. It has strategic partnership and license agreement with Eli Lilly and Company to develop ZP-PTH microneedle patch products; and Novo Nordisk A/S to develop a microneedle patch product to administer semaglutide for the treatment of type 2 diabetes. The company was founded in 2006 and is headquartered in Fremont, California.

26 Employees
Last Reported Date: 03/26/15
Founded in 2006

zosano pharma corp (ZSAN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $412.0K
Chief Medical Officer
Total Annual Compensation: $398.0K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $329.8K
Compensation as of Fiscal Year 2014.

zosano pharma corp (ZSAN) Key Developments

Zosano Pharma Corporation Appoints Joseph 'Jay' P. Hagan to its Board of Directors

Zosano Pharma Corporation announced the election of Joseph 'Jay' P. Hagan to its board of directors, effective May 22, 2015. Mr. Hagan is Executive Vice President, Chief Business & Financial Officer of Orexigen Therapeutics Inc. Mr. Hagan has served as Orexigen's Chief Business & Financial Officer since 2011.

Zosano Pharma Corporation Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015

Zosano Pharma Corporation announced unaudited consolidated financial results for the first quarter ended March 31, 2015. The company reported a net loss for the first quarter of 2015 of $4.6 million, or $0.47 per share on a basic and diluted basis, compared with a net loss of $2.4 million, or $0.46 per share on a basic and diluted basis, for the first quarter of 2014. Total revenue for the first quarter of 2015 was $0.2 million, compared with $1.6 million in the first quarter of 2014. The decrease was primarily due to the non-recurrence in 2015 of license revenue earned in 2014, as a result of the termination of the company's license agreement with Asahi Kasei Pharma. Total debt as of March 31, 2015 was $14.7 million, compared to $22.1 million at the end of 2014. Loss from operations was $4.151 million against $2.568 million a year ago.

Zosano Pharma Corporation Announces Management Changes

Zosano Pharma Corporation announced important leadership additions and changes with Thorsten von Stein, M.D., Ph.D. returning to the company as Chief Medical Officer, Laxmi Peri joining as Sr. Vice President, Operations, and Eric Scharin joining as Vice President, Technical Operations. Mr. Peri will be heading the Operations group including manufacturing and engineering, while Nandan Oza has resigned as Chief Operations Officer and will move to a consulting role with the company. Dr. von Stein resumes his former role at Zosano as Chief Medical Officer having previously served in that position from 2009 to 2014. Before joining Zosano, Dr. von Stein served at Tercica as Senior Vice President and Chief Medical Officer from 2005 to 2009. Laxmi Peri joins Zosano after 11 years as Vice President, R&D at Thoratec Corporation. Eric Scharin most recently served at Zogenix as Senior Director of Engineering and Product Industrialization. He directed all technical programs associated with design engineering, process engineering, facility/project engineering, and validation for Zogenix devices and pharmaceuticals throughout the product lifecycle.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZSAN:US $7.93 USD -0.06

ZSAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $159.08 USD +0.10
Corium International Inc $13.82 USD -0.13
FUJIFILM Holdings Corp ¥4,794 JPY +60.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ZSAN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.9x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOSANO PHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at